These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28807039)

  • 1. The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence.
    Capizzi A; Silvestri M; Orsi A; Cutrera R; Rossi GA; Sacco O
    Ital J Pediatr; 2017 Aug; 43(1):71. PubMed ID: 28807039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
    Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
    Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio Study.
    Silvestri M; Marando F; Costanzo AM; di Luzio Paparatti U; Rossi GA
    Ital J Pediatr; 2016 Apr; 42():40. PubMed ID: 27112952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
    Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
    Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Antibody Treatment of RSV Bronchiolitis in Young Infants: A Randomized Trial.
    Alansari K; Toaimah FH; Almatar DH; El Tatawy LA; Davidson BL; Qusad MIM
    Pediatrics; 2019 Mar; 143(3):. PubMed ID: 30760509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey.
    Prais D; Danino D; Schonfeld T; Amir J
    Chest; 2005 Oct; 128(4):2765-71. PubMed ID: 16236953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
    Staebler S; Blake S
    Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the Updated Guidance for Palivizumab Prophylaxis against Respiratory Syncytial Virus Infection: A Single Center Experience.
    Rajah B; Sánchez PJ; Garcia-Maurino C; Leber A; Ramilo O; Mejias A
    J Pediatr; 2017 Feb; 181():183-188.e1. PubMed ID: 27855996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy.
    Belleudi V; Trotta F; Pinnarelli L; Davoli M; Addis A
    Arch Dis Child; 2018 Dec; 103(12):1163-1167. PubMed ID: 30217858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increasing Rates of RSV Hospitalization among Preterm Infants: A Decade of Data.
    Kong AM; Winer IH; Zimmerman NM; Diakun D; Bloomfield A; Gonzales T; Fergie J; Goldstein M; Krilov LR
    Am J Perinatol; 2023 Oct; 40(14):1529-1536. PubMed ID: 34704241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain.
    Figueras-Aloy J; Carbonell-Estrany X; Quero J;
    Pediatr Infect Dis J; 2004 Sep; 23(9):815-20. PubMed ID: 15361718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
    Prais D; Schonfeld T; Amir J;
    Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 2014-2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States.
    Kong AM; Krilov LR; Fergie J; Goldstein M; Diakun D; Wade SW; Pavilack M; McLaurin KK
    Am J Perinatol; 2018 Jan; 35(2):192-200. PubMed ID: 28881376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospitalization for Respiratory Syncytial Virus Bronchiolitis in the Palivizumab Prophylaxis Era: Need for Reconsideration of Preventive Timing and Eligibility.
    Oz-Alcalay L; Ashkenazi S; Glatman-Freedman A; Weisman-Demri S; Lowenthal A; Livni G
    Isr Med Assoc J; 2019 Feb; 21(2):110-115. PubMed ID: 30772962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
    Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
    Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
    Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
    Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
    Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB
    Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of palivizumab in children with childhood interstitial lung disease: The French experience.
    Drummond D; Thumerelle C; Reix P; Fayon M; Epaud R; Clement A; Mahloul M; Habouria D; Delacourt C; Hadchouel A
    Pediatr Pulmonol; 2016 Jul; 51(7):688-95. PubMed ID: 26636747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.